Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 1324

BRIEF by Amgen Inc. = Bench Memorandum Requesting That The Court Issue A Corrective Instruction That Remedies And Patent Choice Are Irrelevant To The Issues The Jury Must Decide. (Gottfried, Michael)

Download PDF
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 1324 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 1 of 6 `UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS AMGEN INC., v. F. HOFFMANN-LA ROCHE LTD, a Swiss Company, ROCHE DIAGNOSTICS GMBH, a German Company, and HOFFMANN-LA ROCHE INC., a New Jersey Corporation, ) ) ) ) ) ) Civil Action No.: 1:05-cv-12237 WGY ) ) ) ) ) ) ) AMGEN'S BENCH MEMORANDUM REQUESTING THAT THE COURT ISSUE A CORRECTIVE INSTRUCTION THAT REMEDIES AND PATIENT CHOICE ARE IRRELEVANT TO THE ISSUES THE JURY MUST DECIDE During Roche's opening argument on infringement, counsel for Roche improperly argued that jurors should consider "patient choice" when determining whether peg-EPO infringes Amgen's products. Roche also suggested that the jury should consider the remedies at issue in the suit. Roche's arguments are tantamount to a request for jury nullification because they ask the jury to disregard the law of patent infringement in favor of patient choice. Accordingly, Amgen requests that in its Instruction X.A. on Role of the Jury, the following additional language be given to the jury: Finally, as I told you during this trial, my role is also to decide what remedy will be available, if any. You should not speculate about any remedy in this case, or what effect any remedy might have in this case. You should not consider issues of whether patients will or will not have access to MIRCERA, or whether patients should or should not have a choice between Amgen's products and Roche's product (such considerations should not enter your deliberations on any issue in this case). I alone will make that determination. That's my role. It is well-established that counsel should never instruct the jury to disregard the law or to 1 MPK 133539-1.041925.0023 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 2 of 6 consider remedy issues that are not before the jury. Moreover, Roche's arguments directly contravene this Court's Order on Amgen's Motion in Limine No. 12 that Roche not argue that Amgen's patents limit consumer choice. Amgen requests that the court issue a corrective instruction to remedy the prejudice caused by Roche's improper argument. I. Roche's Argument That The Jury Should Ignore The Elements of A Patent Infringement Claim and Consider Patient Choice Were Improper. Roche's arguments about patient choice were totally inappropriate during the infringement phase of this trial. The infringement analysis is a two-step process. First claim language is interpreted as a matter of law. Second, the accused product is compared to the claim limitation to determine whether it falls within the scope of the claim.1 But during Roche's opening, counsel argued: Amgen put up a patient, and what did that patient tell you? The only choice for patients in this country right now is Amgen. Patients have no choice. Roche has developed a new and different drug, which, if approved by the FDA, and allowed by you and this court, will give patients choice for new treatments.2 Roche's arguments about patient choice simply have no place within the jury's analysis, and Roche's implicit plea to the jury to take patient choice into account in deciding the infringement issues or any remedies amounted to a request that it disregard the law. It is well established that it is improper for counsel to ask the jury to disregard the law.3 Indeed, as the First Circuit has stated, "this proscription is invariant; it makes no difference that Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed. Cir. 1995) (Enumerating two step process of infringement analysis). 2 10/03/07 Trial Tr., p. 2374: 20 - 25. 3 United States v. Sepulveda, 15 F.3d 1161, 1190 (1st Cir. 1993) (holding corrective instruction proper as a result of counsel's argument that jury disregard the law); United States v. Desmarais, 938 F.2d 347, 350 (1st Cir. 1991) (holding that "in arguing the law to the jury, counsel is confined to principles that will later be incorporated and charged to the jury"); United States v. Garcia-Rosa, 876 F.2d 209, 226 (1st Cir. 1989) (holding that it is improper for trial judge to tell jury they may disregard the law). 1 MPK 133539-1.041925.0023 2 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 3 of 6 the jury inquired, or that an aggressive lawyer managed to pique a particular jury's curiosity by mentioning the subject in closing argument, or that a napping prosecutor failed to raise a timely objection to that allusion."4 Significantly, Roche's arguments to the jury also directly contradicted the charge the court gave the jury only 15 minutes prior to Roche's opening. Thus, during the charge, the court stated: So we're going to ask you about invalidity. We're going to ask you about infringement. Now we get to infringement. But you're also entitled to know what happens if Amgen, in essence, wins across the board, the patents are valid, the patents are infringed or claims are. Then, under the law, we don't ask the jury any more. But I have something more to do. It's not a foregone conclusion that I will stop Roche from doing what it wants to do. I do have to think about whether I will grant an injunction.5 In disregard of this charge, Roche suggested to the jury that it effectively ignore the requirements of patent infringement and consider another factor, consumer choice. In addition, it affirmatively argued that if the jury found that Roche infringed Amgen's patents, Roche could not sell its product and consumers would not have choice. Roche's argument was patently improper. As the Court stated in its charge, the remedy for infringement and patient choice are not issues for the jury to consider. Indeed, Roche's claim about what happens when the jury finds infringement directly contradicts the Court's charge on whether an injunction will be granted. II. Roche's Arguments About Patient Choice Directly Contravene This Court's Order On Amgen's Motion In Limine No. 12. Roche's improper argument also directly contravenes an order of this Court. Prior to trial, Amgen moved to "exclude reference to Amgen's "monopoly" and the patents-in-suit as 4 5 United States v. Sepulveda, 15 F.3d at 1190. 10/03/07 Trial Tr., p. 2359: 4 12. MPK 133539-1.041925.0023 3 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 4 of 6 limiting consumer choice.6 As set forth in Amgen's Motion, its request for relief was that the court preclude arguments and evidence "that Amgen's patent enforcement will limit or negatively affect consumer choice." On the first day of trial, September 4, 2007, the Court granted Amgen's Motion in Limine. 7 Amgen structured its presentation of witnesses and evidence in reliance upon this order. Thus, Roche's blatant disregard for this Court's order is incredibly prejudicial, and the court should not condone Roche's violation of its orders. In order to rectify the prejudice Roche has caused, Amgen requests that the Court issue a corrective instruction making it clear that patient choice is irrelevant to whether peg-EPO infringes Amgen's patents and that the jury should not consider patient choice or any impact on the potential remedies in the case. Moreover, the court should again instruct the jury that its job is to apply the law of infringement and not to consider the remedies or patient choice as urged by Roche. DATED: October 9, 2007 Respectfully Submitted, AMGEN INC., by its attorneys /s/ Michael R. Gottfried D. Dennis Allegretti (BBO# 545511) Michael R. Gottfried (BBO# 542156) Patricia R. Rich (BBO# 640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: (857) 488-4200 Facsimile: (857) 488-4201 Of Counsel: Stuart L. Watt Wendy A. Whiteford Monique L. Cordray Darrell G. Dotson Kimberlin L. Morley Erica S. Olson AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 (805) 447-5000 6 7 See Docket No. 847. See Electronic Order entered Sept. 4, 2007 granting Docket No. 847. MPK 133539-1.041925.0023 4 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 5 of 6 Lloyd R. Day, Jr. (pro hac vice) DAY CASEBEER MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: (408) 873-0110 Facsimile: (408) 873-0220 William G. Gaede III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: (650) 813-5000 Facsimile: (650) 813-5100 Kevin M. Flowers (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago, IL 60606 Telephone: (312) 474-6300 Facsimile: (312) 474-0448 MPK 133539-1.041925.0023 5 Case 1:05-cv-12237-WGY Document 1324 Filed 10/09/2007 Page 6 of 6 CERTIFICATE OF SERVICE I hereby certify that this document filed through the Electronic Case Filing (ECF) system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants on the above date. /s/ Michael R. Gottfried Michael R. Gottfried MPK 133539-1.041925.0023

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?